Radiolabelled peptides for oncological diagnosis

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmaceutical science

Background:

• Radiolabeled receptor-binding peptides are investigated for targeting tumors.
• The in vivo targeting of receptor-expressing tissues using radiolabeled peptides is a key area in nuclear medicine research.
• The (111)In-labeled somatostatin analogue octreotide (OctreoScan) is a leading radiopeptide for tumor imaging and the first approved diagnostic radiopeptide.

Purpose of the Study:

• To review various receptor-targeting peptides and their analogues.
• To discuss the potential of these peptides for radionuclide imaging of tumors.

Main Methods:

• Review of existing literature on radiolabeled peptides for tumor imaging.
• Discussion of specific peptide classes including somatostatin analogues, cholecystokinin/gastrin analogues, glucagon-like peptide-1, bombesin (BN), chemokine receptor CXCR4 targeting peptides, and RGD peptides.

Main Results:

• Octreotide (OctreoScan) is the most successful radiopeptide for tumor imaging to date.
• Several other receptor-targeting peptides are in development or clinical trials for diagnostic applications.
• These peptides target receptors overexpressed on tumor cells.

Conclusions:

• Radiolabeled peptides offer significant potential for the diagnosis and therapy of cancer.
• Ongoing research and clinical trials are expanding the range of available radiopeptides for nuclear medicine applications.
• The development of novel receptor-targeting peptides is crucial for advancing radionuclide tumor imaging.